{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-021482","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.223114+00:00","generated_at":"2026-05-18T14:43:44.384756+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Allarity dosed second patient in new Phase 2 stenoparib trial for advanced ovarian cancer","bullets":["Second patient dosed in new Phase 2 trial of stenoparib for advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.","CEO Thomas Jensen cited strong investigator engagement and rapid enrollment pace.","Trial builds on prior Phase 2 data showing durable benefit and favorable tolerability with twice-daily dosing.","Stenoparib is a dual PARP and WNT pathway inhibitor; trial also advances DRP companion diagnostic.","Current platinum-resistant patients have limited treatment options; stenoparib aims to offer a better-tolerated alternative."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-021482","json":"https://secwatch.observer/filing/0001437749-25-021482.json","markdown":"https://secwatch.observer/filing/0001437749-25-021482.md","text":"https://secwatch.observer/filing/0001437749-25-021482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925021482/0001437749-25-021482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925021482/allr20250630_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T14:43:44.384756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}